Neumora Therapeutics terminated development of navacaprant after two late-stage failures in its phase 3 program for major depressive disorder, KOASTAL-2 and KOASTAL-3. Following the discontinuation, the company said it will cut 35% of its workforce as it shifts focus to earlier pipeline candidates, with management framing the layoffs as cost saving pending additional clinical updates.